In patients treated by PCI before April 2002, the in-hospital cost was ¥1,456,375±358,781. The costs of PCI and PCI devises were ¥1,314,159±357,301 and ¥1,069,819± 357,010, respectively, which were 90% and 73% of the total in-hospital cost. Table 1 presents the number of devices used, previous and current prices of PCI devices in Japan and those in the USA. When the current prices of PCI devices are used in the recalculation of the in-hospital cost of those patients, there is a 7% reduction (ie, in-hospital cost = ¥1,355,812±313,237). The cost of the PCI device is ¥935,256±311,494 (13% reduction). If the prices of the devices were reduced to those in USA, in-hospital and PCI device costs would be ¥689,417±99,139 (53% reduction) and ¥268,861±96,534 (75% reduction), respectively.
ecause of the prolonged recession, structural reform has been implemented in Japan and the Government sponsored, Japanese health insurance system has not been exempted. Heated debate on reform of the medical insurance system was held in the last Diet session. Because of increasing medical expenses as a result of the growing elderly population, the medical insurance system is mired in red ink, with almost all health insurance associations currently in the red. In this situation, physicians must be more cost-conscious, but little attention has been paid to cost analysis in Japan. 1 It has been known for a long time that medical devices are much more expensive in Japan than in the United States (USA), [1] [2] [3] [4] [5] [6] [7] so in April 2002 the prices of medical devices, such as pacemaker and percutaneous coronary intervention (PCI) devices, were reduced, in an attempt to save medical expenses. This study evaluated the impact of that change in the price of PCI devices on medical expenses.
Methods
The in-hospital costs of 22 consecutive patients who underwent elective single-vessel PCI without debulking procedure at Sawara Hospital in Chiba, Japan before April 2002 were collected. Coronary stenting was performed in 18 of the 22 patients and procedural success was achieved in all patients except 1 with chronic total occlusion. There were no major in-hospital complications. Non-Q-wave myocardial infarction occurred in 1 patient. None had a vascular complication that required a longer hospital stay. When patients had other diseases such as diabetes mellitus, the medical cost of those diseases was excluded. Changes in the technique of PCI and modification of the devices affect catheterization laboratory resource utilization, and subsequently in-hospital cost. To evaluate the pure reduction of in-hospital cost by a change in the prices of the PCI devices catheterization laboratory resource utilization, such as the number of balloon catheters and stents used, must be the same. Thus we recalculated the in-hospital cost of each patient by applying the current prices of PCI devices. 1 In addition, to evaluate the difference in the in-hospital cost between Japan and USA because of the different prices of the PCI devices, it was recalculated using the USA prices ($1 = ¥120). [2] [3] [4] of financial crisis. Medical expenses in Japan increased from 20 trillion yen in the fiscal year 1989 to 31 trillion yen in the fiscal year 1999 (the statistical reports of the Health, Labor and Welfare Ministry in Japan). More than 1,700 corporate insurance societies are making losses, the combined total of which is likely to amount to 500 billion yen this fiscal year. Heated discussion was held in the last Diet session, and reforms of the medical insurance system, such as increase in a salaried worker's payment for a medical expense and a decrease in medical insurance reimbursements, were decided. However, it might be difficult to improve the economic situation of the insurance system and thus fundamental reform of the medical insurance system may be inevitable. In that situation, physicians are required to be more cost-conscious and to treat patients efficiently, although there must not be any impairment of quality of care. Although considerable attention has been paid to cost analysis in the USA, 2-7 it has not been fully discussed in Japan. 1 Increasing demand for PCI is placing a large financial burden on limited healthcare resources. The Japanese Coronary Intervention Study Group conducted a nationwide survey on coronary revascularization procedures during 1997 and reported that a total of 109,788 PCI and 17,667 coronary artery bypass procedures were performed in Japan. 8 The ratio of PCI to coronary artery bypass surgery was 6.2, which is much higher than in the USA. 8 Thus reduction in the cost of PCI in Japan, especially of the PCI device, which constitutes 73% of the total in-hospital cost, is important. Even though some of patients may have multivessel coronary intervention, it can be roughly estimated that the change in the prices of PCI devices in April 2002 saves ¥11 billion/year [¥(1,456,375-1,355,812) ×109,788].
PCI devices are much more expensive in Japan than in USA or Europe (Table 1) , [1] [2] [3] [4] 9, 10 and although the change in the prices in April 2002 reduces the gap slightly, the devices are still much expensive in Japan, even though most are imported. If the prices were reduced to those in the USA, it would save medical expenses of ¥73 billion/year [¥(1,355,812-689,417) ×109,788]. The numbers of balloon catheters and stents for reimbursement have been less since April 2002, but there are cases with complex lesions that require more devices. If the prices of the devices were reduced to those in the USA, we might be allowed to use the devices as required. Deregulation of the competition in the interventional products is necessary to reduce stent and angioplasty equipment prices.
It has been reported that the difference in overall (inhospital + follow-up) cost between conventional balloon angioplasty and stenting would be ¥74,016 in the USA (¥1,098,807 vs ¥1,172,823), whereas it is ¥375,655 in Japan (¥1,188,583 vs ¥1,564238). 1 Few modern medical advances are truly cost-saving, and many wide-spread practices, including bypass surgery for left main disease, 11 -blocker therapy after acute myocardial infarction 12 and thrombolytic therapy for acute myocardial infarction 13 prolong life only at the expense of increased healthcare costs. Nevertheless, such treatments are viewed as costeffective because their benefits to the patient are 'worth the additional cost'. From this viewpoint, stenting is considered to be 'worth the additional cost' (¥74,016) in the USA, but the cost difference in Japan (¥375,655) may be too high for such justification. Recently, a dramatic reduction in the rate of restenosis has been demonstrated with drug-eluting stents. 14 The projected cost of a drug-eluting stent is likely to be approximately $3,200, which is almost 3-fold more expensive than a bare stent. 15 Thus it might cost one million yen in Japan and all patients might not be able to receive the benefit of drug-eluting stents.
Recent randomized studies demonstrated long-term outcomes in patients with multivessel disease treated with multivessel stenting compared with CABG. [16] [17] [18] The longterm mortality was controversial, although target revascularization rates were higher in the stent group than in the surgery group. [16] [17] [18] Cost analysis of multivessel stenting and coronary bypass surgery in the USA and Europe showed a lower overall (in-hospital and follow-up) cost in the stent group, 16, 19 but a study in Argentine where stenting is much more expensive ($3,000) than in the USA and Europe, as in Japan, demonstrated no difference in the overall cost between the 2 techniqes. 17 There has been a comparison of the long-term outcome of medical therapy and PCI, particularly in patients with single-vessel disease, which showed that long-term mortality, myocardial infarction, and target lesion revascularization were similar between the 2 therapy groups, but that PCI was superior to medical treatment for the alleviation of angina. 20 Overall cost was less in the medical therapy group than in the PCI group. 9 Thus, particularly in the face of constraints on healthcare spending, it may be recommended that physicians reserve PCI for patients with single-vessel disease whose symptoms of angina are not well controlled by medical treatment. 20 Because of the Government sponsored, Japanese health insurance system, all Japanese citizens are able to receive the best treatment equally. However, the nation's health insurance system is on the verge of a financial crisis and so physicians must be more cost-conscious, and furthermore everyone in Japan must consider reforms to the medical insurance system. Otherwise physicians may not be able to provide the best treatment for all patients equally.
Study Limitations
The in-hospital cost of patients treated before April 2002 was recalculated by applying the current device prices and those in the USA to estimate those after the change in the prices and in USA. 1 The difference in catheterization laboratory resource utilization affects in-hospital cost. Furthermore, the method of calculating in-hospital cost and the reimbursement system are completely different between Japan and the USA. [1] [2] [3] [4] [5] [6] [7] That is why we used this method to evaluate the pure difference in the in-hospital cost because of the different device prices. 1 Reimbursement prices of the devices were used to calculate the in-hospital cost in Japan. On the other hand, market prices are used in the USA, because there are no reimbursement prices. Thus the difference in the prices of the PCI devices may be less; however, even considering this possible disagreement, PCI devices are much more expensive in Japan. 1 
Conclusions
The change in the prices of PCI devices in April 2002 reduces the in-hospital cost by 7%. However, the devices are still much more expensive in Japan than in USA and further reduction of the prices is required to make PCI more cost-effective.
